PMC:7536954 / 607-937 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T14","span":{"begin":38,"end":56},"obj":"Disease"},{"id":"T15","span":{"begin":51,"end":56},"obj":"Disease"},{"id":"T16","span":{"begin":93,"end":95},"obj":"Disease"},{"id":"T17","span":{"begin":101,"end":104},"obj":"Disease"},{"id":"T18","span":{"begin":212,"end":220},"obj":"Disease"},{"id":"T19","span":{"begin":258,"end":260},"obj":"Disease"},{"id":"T20","span":{"begin":265,"end":268},"obj":"Disease"},{"id":"T21","span":{"begin":283,"end":291},"obj":"Disease"},{"id":"T22","span":{"begin":292,"end":301},"obj":"Disease"}],"attributes":[{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0016474"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0004670"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0006559"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0007915"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0006559"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0007915"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"f TNF‐α inhibitors due to the risk of drug‐induced lupus. 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐la"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":2,"end":5},"obj":"http://purl.obolibrary.org/obo/PR_000000134"},{"id":"T11","span":{"begin":125,"end":130},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"f TNF‐α inhibitors due to the risk of drug‐induced lupus. 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐la"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":8,"end":18},"obj":"Chemical"},{"id":"T6","span":{"begin":38,"end":42},"obj":"Chemical"},{"id":"T7","span":{"begin":93,"end":95},"obj":"Chemical"},{"id":"T8","span":{"begin":125,"end":130},"obj":"Chemical"},{"id":"T9","span":{"begin":258,"end":260},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_74056"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_74056"}],"text":"f TNF‐α inhibitors due to the risk of drug‐induced lupus. 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐la"}

{"project":"LitCovid-PubTator","denotations":[{"id":"31","span":{"begin":2,"end":7},"obj":"Gene"},{"id":"32","span":{"begin":245,"end":252},"obj":"Species"},{"id":"42","span":{"begin":101,"end":104},"obj":"Disease"},{"id":"43","span":{"begin":212,"end":220},"obj":"Disease"},{"id":"44","span":{"begin":265,"end":268},"obj":"Disease"},{"id":"45","span":{"begin":283,"end":291},"obj":"Disease"},{"id":"46","span":{"begin":292,"end":301},"obj":"Disease"}],"attributes":[{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Gene:7124"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"Tax:9606"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D008180"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:C000657245"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D008180"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:C000657245"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"f TNF‐α inhibitors due to the risk of drug‐induced lupus. 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐la"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":93,"end":95},"obj":"Phenotype"},{"id":"T11","span":{"begin":101,"end":104},"obj":"Phenotype"},{"id":"T12","span":{"begin":258,"end":260},"obj":"Phenotype"},{"id":"T13","span":{"begin":265,"end":268},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0040154"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0002725"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0040154"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0002725"}],"text":"f TNF‐α inhibitors due to the risk of drug‐induced lupus. 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐la"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":58,"end":230},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"f TNF‐α inhibitors due to the risk of drug‐induced lupus. 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐la"}